Life Science Practice

Edgewater’s Life Science Practice is focused on companies that create value by providing critical products or services towards the development or manufacture of pharmaceuticals, biopharmaceuticals, diagnostics and medical devices. The dynamic and rapidly growing target verticals are focused on companies providing pharmaceutical fine chemicals, pharmaceutical services (CRO, CDMO, CMO, and niche specialist players), and companies offering differentiated reagents, materials, and technologies to the pharma industry.

View our Pharma Chemicals teaser

Target Industries, End Markets, or Applications

Pharma Chemicals

Chemical intermediates

Regulatory starting materials

Active pharmaceutical ingredients

Differentiated capabilities

Batch or continuous processing capabilities

Pharma Services Organizations

CRO, CDMO, CMO

Small molecules/large molecules (proteins/antibodies; gene/cell therapy)

Niche companies in Drug Development or CMC-focused

Active ingredients, pre-formulation, formulation, packaging

Analytical/assay development services, Bioanalytical

Discovery, pre-clinical, clinical, commercial

Reagents, Materials and Technologies

Chemical or biological reagents for research, diagnostics, or commercial use

Enabling technologies (i.e., enzymes, catalysts, biologic processes)

Functional materials (e.g., functional excipients, adjuvants)

Diagnostics

Practice Leader: Brian Scanlan

Practice Leader:
Brian Scanlan

bscanlan@edgewatercapital.com
Office: (216) 292-3838

Brian leads Edgewater’s Life Science practice and is engaged with several portfolio companies in advisory roles spanning commercial, operational, and Board advisory. Brian has spent nearly three decades in the pharmaceutical services sector, developing and growing companies offering highly differentiated technologies and services. He is also the Founder and Managing Partner of Freedom Bioscience Partners, a consultancy firm focused on M&A and strategic business advisory to the pharmaceutical and fine chemical industries. Prior to launching Freedom, Brian served as CEO at Cambridge Major Laboratories, a global pharma contract development and manufacturing organization (CDMO) focused on active pharmaceutical ingredients, solid state chemistry, and analytical services.

Brian holds a BS in Chemistry from Northern Illinois University and an MBA from the Illinois Institute of Technology.